Vol. I · Est. 2025 · Houston, TX
Peptide Atlas
The Complete Map of Peptide Research
PCAC Result
BPC-157Rec. 503A
TB-500Rec. 503A
KPVRec. 503A
MOTS-cRec. 503A
SemaxRec. 503A
EpitalonRec. 503A
DSIPDeclined
Transparency & Methodology

About Peptide Atlas

Everything you need to know about who built this, why, how we make money, and how our scoring works. Nothing hidden.

Ownership

Peptide Atlas is created by Lone Star Peptide Co.

Lone Star Peptide Co. is a Houston, Texas-based research-use-only peptide supplier. We created Peptide Atlas because the information environment in this space is broken: vendor blogs written to sell product, paywalled newsletters gating basic reference data, and forum threads with no accountability or citations.

We are disclosing this ownership prominently and permanently — not as a footnote, but as a feature. A vendor that publishes a directory that could point users to competitors is demonstrating confidence. That confidence is the editorial product.

Disclosure Statement
Lone Star Peptide Co. owns and operates Peptide Atlas. LSPC is listed in the Vendor Directory as a sponsored listing. Our transparency score (currently 85/100) is calculated by the same methodology as all other vendors. Sponsorship does not affect our score. Editorial content is maintained independently of commercial interests. If you believe editorial content has been influenced by commercial interests, contact us.

Peptide Atlas operates under the Lone Star Holdings umbrella alongside Lone Star Peptide Co. and other subsidiaries. Each operates independently with separate domains and analytics.

Questions about ownership: adam@lonestarpeptideco.com

Editorial Methodology

How we write compound pages

Every compound page on Peptide Atlas follows the same structure: mechanism, evidence summary, divergence analysis, dose reference, safety profile, and regulatory status. We do not vary this structure based on how "interesting" a compound is or how it would affect sales.

Evidence grading: We use plain-language descriptors rather than formal scoring systems. "Preclinical only" means no published human clinical data. "Phase 2" means a human clinical trial has been completed at that stage. "FDA Approved" means exactly that. We do not conflate these categories.

Divergence: The divergence indicator — High, Moderate, Low — reflects how closely community dosing protocols match published clinical or preclinical research. High divergence does not mean a protocol is dangerous. It means we cannot evaluate it against research because the research does not exist. This is the honest answer, and it is the answer you will not find on vendor blogs.

Sources: We draw on PubMed-indexed research, FDA.gov for regulatory status, ClinicalTrials.gov for trial status, and community forum data (clearly labeled as such) for dose reference figures. We do not cite unpublished claims or vendor-funded research without disclosure.

Vendor Transparency Scoring

How the 0–100 score is calculated

The Vendor Transparency Score is calculated entirely from submitted documentation. Vendors self-report; we verify what we can. Payment tier does not affect score.

CriterionPointsWhat it means
Batch-specific COA30Certificate of Analysis tied to the specific batch being sold. Not a generic COA. This is the most important transparency signal.
Finnrick test data20Third-party testing via Finnrick Labs, which tests RUO peptides specifically. Highest-credibility third-party verification available in this space.
Domestic US fulfillment15Ships from a US address. Reduces import uncertainty and cold-chain risk.
Business information verified15Business registration, physical address, and owner identity verifiable. Not a PO box or anonymous storefront.
Cold-chain available10Refrigerated shipping available on request. Relevant for peptide stability.
ACH / Invoice payment10Accepts ACH transfer or formal invoice. Signals legitimate business operations and allows institutional buyers to transact properly.

Scores are updated when vendors submit updated documentation. Sponsored listings are labeled. All sponsored placements are disclosed in every vendor card. A vendor paying for a premium placement cannot improve their score by doing so.

Business Model

How Peptide Atlas makes money

Peptide Atlas is monetized through three disclosed channels:

01
Vendor Directory Sponsorships
Vendors pay for listings ($199–$1,500/month depending on tier). All sponsored listings are labeled. Scores not affected by payment.
02
Newsletter Sponsorships
The Peptide Research Digest accepts newsletter sponsors. Sponsored issues are labeled. Editorial coverage is never sold.
03
LSPC Brand Authority
Peptide Atlas builds authority for Lone Star Peptide Co. as a credible vendor. This is an indirect benefit, disclosed here.
04
No paywalls. Ever.
All reference content is free. No email gate on compound pages, dose references, or regulatory tracking. The newsletter is opt-in.

We do not accept payment to write favorable editorial coverage. We do not accept payment to improve vendor scores. We do not run banner ads. Anthropic does not display ads in this interface. Peptide Atlas is an editorial business — the authority is the product, and selling it would destroy it.

Disclaimers

Medical, RUO, and legal disclaimers

Medical disclaimer: Nothing on Peptide Atlas is medical advice. Compound pages, dose reference data, safety profiles, and regulatory information are published for educational and research reference purposes only. Do not use any information on this site to make medical decisions. Consult a licensed medical professional.

RUO disclaimer: Research Use Only (RUO) compounds are not intended for human consumption. RUO designation means a product is sold for research purposes only and has not been evaluated by the FDA for safety or efficacy in humans. Community dosing data on this site is cited for informational and reference purposes only. It does not constitute instruction or encouragement to use these compounds.

Regulatory accuracy: Regulatory status information is updated manually. We cannot guarantee real-time accuracy. Always verify compound status at FDA.gov before making any legal or commercial decisions.

Not legal advice: Nothing on this site constitutes legal advice regarding regulatory compliance, compounding law, or any other legal matter. Consult a qualified attorney.

Contact

Reach us

General inquiries: adam@lonestarpeptideco.com

Vendor listings: Use the "Request Media Kit" button on the Vendor Directory.

Editorial corrections: If you believe any content is factually incorrect, email us with a source and we will review and update.

Lone Star Peptide Co.: lonestarpeptideco.com · Houston, TX 77043

Free Research Digest
The Peptide Research Digest
Regulatory updates, new compound coverage, and vendor transparency changes. No sales pitch.
No spam · Unsubscribe any time